Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 9/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1029129 | 0.83 | PLK1 (0.52) | S1PR1S1PR4S1PR5S1PR3PLK1 | |
| SCHEMBL8189421 | 0.75 | PLK1 (0.51) | S1PR1FFAR4PTGDR2PLK1GAA | |
| SCHEMBL10088515 | 0.75 | NOTUM (0.44) | NOTUMGAAPTGS2 | |
| Hydrochloric Acid SCHEMBL8189425 | 0.74 | PLK1 (0.53) | S1PR1NOTUMPTGDR2PLK1GAA | |
| SCHEMBL3901410 | 0.72 | S1PR1 (0.49) | S1PR1S1PR4S1PR5S1PR3PLK1 | |
| SCHEMBL8419554 | 0.72 | PLK1 (0.42) | S1PR1S1PR4S1PR5S1PR3FFAR4 | |
| SCHEMBL16048909 | 0.71 | FFAR4 (0.55) | NOTUMFFAR4PTGDR2 | |
| SCHEMBL2850192 | 0.70 | ESR1 (0.41) | NOTUMGAAPTGS2 | |
| SCHEMBL12490208 | 0.70 | PTPN2 (0.36) | — | |
| SCHEMBL12490646 | 0.68 | PTPN2 (0.41) | S1PR1S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | S1PR1 1/4885S1PR4 5/4885S1PR5 4/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885S1PR4 3/4885S1PR5 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.